Structure Therapeutics reported robust Phase IIb results for its oral GLP‑1 candidate aleniglipron showing up to ~15% weight loss, re‑establishing the company in the small‑molecule obesity race. The mid‑stage readout landed amid heightened scrutiny of tolerability for oral agents and renewed investor interest in oral alternatives to injectable GLP‑1s. A companion headline and market response noted Structure’s data compare favorably with other oral entrants and peptide competitors, but analysts flagged tolerability and long‑term durability as open questions. The company’s results were presented in industry coverage and triggered sharp share moves for peers. These data escalate competition among oral GLP‑1 developers and will influence licensing, partnering and regulatory strategies across big pharma and biotech.